According to Ellen Drazen, spokeswoman for Express Scripts, the pharmacy benefit manager (PBM) has not involved itself in any partnership with Kaleo for its emergency allergy treatment Auvi-Q, reported TheStreet.
Kaleo said last week that it would be re-introducing its auto-injector on the US market in February under a pricing scheme that will make the product free for insured patients, as well as for uninsured patients with a household income of less than $100 000, and cost $360 for other uninsured patients, but will cost $4500 for insurance companies and PBMs.
"Regarding Auvi-Q, we believe this is another egregious pricing scheme that will attempt to gouge payers and damage our healthcare system," Drazen said.
Karen Eldred, spokeswoman for Cigna, remarked that "the price for Auvi-Q far exceeds that of epinephrine alternatives with the same expected medical results. Therefore, we have no plans to add Auvi-Q to our covered drug lists."
Cigna will cover the generic version of Adrenaclick, as well as the generic version of Mylan's EpiPen, which was introduced in December for $300 for a two-pack.
Meanwhile, although UnitedHealth Group did not respond to immediate request for comment, a source said that Optum, the healthcare company's PBM, would not pay for Auvi-Q. CVS Caremark could not be reached for immediate comment, the news source said.
To read more NewsPoints articles, click here.